A policy for leishmaniasis with respect to the prevention and control of drug resistance. - Wikidata - awgldk - TriplyDB

A policy for leishmaniasis with respect to the prevention and control of drug resistance.

A policy for leishmaniasis with respect to the prevention and control of drug resistance.

http://www.wikidata.org/entity/Q38924387

about

Strategies to overcome antileishmanial drugs unresponsiveness A Luciferase-Expressing Leishmania braziliensis Line That Leads to Sustained Skin Lesions in BALB/c Mice and Allows Monitoring of Miltefosine Treatment Outcome Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent Leishmania donovani develops resistance to drug combinations Drug resistance in leishmaniasis Elimination of visceral leishmaniasis on the Indian subcontinent.Treatment of visceral leishmaniasis.Production and characterization of stable amphotericin-resistant amastigotes and promastigotes of Leishmania mexicana.Frequency of drug resistance gene amplification in clinical leishmania strains Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects.Comparative activities of the triterpene saponin maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamsters Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B.In vitro and in vivo interactions between miltefosine and other antileishmanial drugs Treatment options for visceral leishmaniasis.Treatment of visceral leishmaniasis: a review of current treatment practices.Structures, targets and recent approaches in anti-leishmanial drug discovery and development.Combination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of Leishmania spp. to Miltefosine by inhibiting drug efflux CpG oligodeoxynucleotide 2006 and miltefosine, a potential combination for treatment of experimental visceral leishmaniasis.Use of antimony in the treatment of leishmaniasis: current status and future directions.Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children Leishmania is not prone to develop resistance to tamoxifen.Novel approach to in vitro drug susceptibility assessment of clinical strains of Leishmania spp Novel Agents against Miltefosine-Unresponsive Leishmania donovani.The relationship between leishmaniasis and AIDS: the second 10 years The role of ISCOMATRIX bilayer composition to induce a cell mediated immunity and protection against leishmaniasis in BALB/c mice.Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species.TLR9 and MyD88 are crucial for the maturation and activation of dendritic cells by paromomycin-miltefosine combination therapy in visceral leishmaniasis Drug delivery strategies for therapy of visceral leishmaniasis.Treatment Outcome of the Drug-resistant Zoonotic Cutaneous Leishmaniasis by Glucantime Cutaneous leishmaniasis: therapeutic strategies and future directions.Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda.American cutaneous leishmaniasis in infancy and childhood.Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: report of four cases.Adherence to miltefosine treatment for visceral leishmaniasis under routine conditions in Nepal.In vitro antileishmanial activity of fisetin flavonoid via inhibition of glutathione biosynthesis and arginase activity in Leishmania infantum.Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis.Drug resistance in leishmaniasis.

P2860

Q26849297-387599F3-D6FB-4A5F-97A4-AAB7CE2E4F7A Q27303693-DF2E71F9-2498-451D-83F3-5940DAF9D5C2 Q28241775-4B7E29BC-EE29-4B3E-82A5-2625F54BBC60 Q28285948-216106A0-9C70-4E36-B386-36C8CA69D705 Q28475431-AA3797D2-5E57-4D1C-8E7E-6046962C1CC0 Q28484463-1927CED1-4113-4805-8B76-61BD8DD6990A Q29616242-AF82F751-FFD9-4DA4-A3C7-8C89E9FFC773 Q30244956-5359F936-A87D-4596-B6E1-06216FC61B37 Q33929849-4A1B6D53-2B53-496E-A23F-FC16B28B3DBF Q33938137-E1972F37-26E5-41C3-94EF-FADAC23FD757 Q34034590-FEEC97D6-F6DB-4DA7-A582-FACF78BBB51D Q34054948-F4149A5C-F59A-4373-B336-0CBD5B6FD63E Q34141596-AA512545-02F5-47CF-9D2E-DBD3784F3979 Q34230457-B8FB0C66-16D8-481B-A7C2-95305F698C10 Q34301638-56D0227C-4307-4CFF-AD84-222DBFF653FB Q34510966-A805AB4A-EF5A-411B-9D2F-36BFFE0C9DD7 Q34768497-F12828A0-C7D1-487A-9FCB-7C2778E31C18 Q35012968-D5D71B31-FC22-4916-B25D-0A25297A8225 Q35023368-413FA8B7-B3B0-4AA1-9B6C-722D2178FCEA Q35065830-112D5B07-28CA-4804-BAB4-B0C755322A10 Q35377767-7618E332-351A-4FD4-86A1-EAB571EE1874 Q35694752-AB1059E5-844F-49AA-AFA2-ECE909108997 Q35801671-6611565C-4D0C-4FB2-B208-EEE21DFA2448 Q36118602-64B38D28-8E20-49B7-894D-4D496CA9E7C2 Q36290836-D196ABD0-B681-4A14-9A90-E41185B455D5 Q36538814-DFA310AD-BB47-4357-BBD4-192EBD5F25DD Q36758235-1B0E6986-E355-4260-A5B5-882329535DC2 Q36803937-2FDBF687-3B54-4397-9893-374094309547 Q37544280-F2B93E78-7323-4541-B21F-16A69F7924CC Q37635270-A444664A-F63C-4545-B377-489E5B3C79E6 Q37702257-CDF69F4B-62C6-4BEC-91DD-2DF33D7E2035 Q37704808-9FDC891A-C692-4D69-AA13-ACF29859D9FC Q38872459-B68B20B1-B0F2-48E4-B867-570E93F633E8 Q38876841-974850E3-9659-463D-AE90-387B6DA21060 Q39336818-931707CE-4D6A-4137-A838-D880D517CBD3 Q39341928-6AFDA28A-DBAE-4DB5-B672-51DAFA53CC4D Q39510687-D1AD070E-E112-42DD-8546-C17186287C05 Q40261768-31E7E138-0A63-4A46-B619-0F1940AA1EED Q40802236-9047401D-3A64-4C94-ADEF-EB328A68DF90 Q41271991-451AC6C2-FAD0-4286-A325-1B23F0B67464

P2860

A policy for leishmaniasis with respect to the prevention and control of drug resistance.

http://www.wikidata.org/entity/Q38924387

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh

2001年學術文章

@zh-hant

name

A policy for leishmaniasis with respect to the prevention and control of drug resistance.

@en

type

label

A policy for leishmaniasis with respect to the prevention and control of drug resistance.

@en

prefLabel

A policy for leishmaniasis with respect to the prevention and control of drug resistance.

@en

P1433

Q38924387-0D1B9595-AB08-4C74-8A49-D2DCB8387B6C

P1476

Q38924387-0A35B519-E959-4AB3-8893-307AFA6E1097

P2093

Q38924387-E9134215-2FE4-4F6E-A13A-B776BFB169DA

P2860

Q38924387-009A88B0-6D97-45B5-A9BB-216AF97C47C6

Q38924387-1EE97ABF-F958-420F-B9E6-D173B821BF7E

Q38924387-224A7221-9D10-4B66-8526-D03E877F556F

Q38924387-25CC9F1B-0C46-4CB7-9535-4A51A3BD16D9

Q38924387-5481ADCE-A6E3-4CB5-B444-5C8582011824

Q38924387-55D4E149-DEA6-45C2-AA3F-F4F422F8FA12

Q38924387-648EF3C8-9629-473E-B498-5E43DE46E1AB

Q38924387-6DAF2777-179D-499C-9ABB-28E75A93DB02

Q38924387-7EED784E-8133-4F4D-8E67-EE1B321384A1

Q38924387-863A752D-07EE-429F-8A93-8721500DC8BD

P304

Q38924387-0848CAEB-4A8E-4634-BE5E-F5B091AC0F9F

P31

Q38924387-0E27B0FE-A626-44D8-A1C8-DD9BBE7127C7

P356

Q38924387-02B87FD4-2405-43AB-94E0-07423606812A

P433

Q38924387-FECC984C-2E56-4993-842E-98D21CA1E114

P478

Q38924387-AE92D3A9-52A9-4F34-870D-C1AC0C19D21A

P577

Q38924387-C7CEEEF9-7185-44E0-9A14-6C3486F989F7

P5875

Q38924387-7E060D6E-5555-4126-9377-102CDF7DDC88

P698

Q38924387-2FA0E843-B9F1-4810-B781-8BDD295FED07

P356

J.1365-3156.2001.00795.X

P1433

Tropical Medicine and International Health

P1476

A policy for leishmaniasis with respect to the prevention and control of drug resistance.

@en

P2093

Bryceson A

http://www.w3.org/2001/XMLSchema#string

P2860

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment

Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine.

Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.

Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis.

The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994.

Investigation of the spread of human visceral leishmaniasis in central Tunisia.

Visceral leishmaniasis unresponsive to antimonial drugs. II. Response to high dosage sodium stibogluconate or prolonged treatment with pentamidine.

Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance.

Visceral leishmaniasis and HIV-1 co-infection in southern France.

P304

928-934

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-3156.2001.00795.X

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2001-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11650600

http://www.w3.org/2001/XMLSchema#string

P698

11703848

http://www.w3.org/2001/XMLSchema#string